Plain-English translation of NCT07914907 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Rheumatoid arthritis causes progressive joint damage that can lead to disability if not treated early and aggressively. This study evaluates whether an artificial intelligence tool can help doctors make better decisions about assessing your risk of bone erosion and choosing the right disease-modifying antirheumatic drugs (DMARDs) to protect your joints. Your doctor will make treatment decisions twice—once based on standard clinical information, and again after reviewing an AI-generated report—to see if the technology improves care quality.
Current methods for predicting joint damage and selecting the right medication can be inconsistent, and some patients develop irreversible disability because treatment wasn't started or adjusted quickly enough. This trial is testing whether this medication can help doctors integrate complex medical information more reliably and make more consistent, evidence-based treatment choices in routine hospital care.
You likely qualify if…
You likely don't qualify if…
As an inpatient receiving routine care for rheumatoid arthritis, your doctor will first assess your risk of joint damage and recommend a treatment plan based on standard clinical information. After that, your doctor will review an AI-generated report with risk predictions and treatment suggestions, then update their assessment. Your medical information—including blood tests, imaging, and clinical history—will be used to generate the AI report. You keep the right to refuse any recommended treatment; your doctor makes all final decisions about your care.
AI-generated summary from trial data · Nov 9, 2026 · Not medical advice
China